# Phase II Dose Ranging Study of Artesunate

> **NCT00459615** · PHASE2 · COMPLETED · sponsor: **U.S. Army Office of the Surgeon General** · enrollment: 120 (estimated)

## Conditions studied

- Falciparum Malaria
- Uncomplicated Malaria

## Interventions

- **DRUG:** Artesunate for Injection

## Key facts

- **NCT ID:** NCT00459615
- **Lead sponsor:** U.S. Army Office of the Surgeon General
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2007-12
- **Final completion:** 2008-01
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2008-09-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00459615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00459615, "Phase II Dose Ranging Study of Artesunate". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00459615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*